The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension

Saudi Medical Journal

Volumn 36, Issue 10, 2015, Pages 1151-1155

  Wang, Hui Bo ^a   Yang, Jun ^a  

^a CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 124; MICRORNA 132; MICRORNA 135A; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 181A; MICRORNA 212; MICRORNA 421; MICRORNA 483 3P; UNCLASSIFIED DRUG;

DOWN REGULATION; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; GENETICS; METABOLISM;

HUMANS; HYPERTENSION; MICRORNAS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84944249007     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: 10.15537/smj.2015.10.12458     Document Type: Review

References (48)

1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219.
3. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet 2015. pii: S0140-6736(14)61468-9.
4. Batkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep 2012; 14: 79-87.
5. Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011; 124: 175-184.
6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
7. McManus DD, Ambros V. Circulating MicroRNAs in cardiovascular disease. Circulation 2011; 124: 1908-1910.
8. Van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117: 2369-2376.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
10. Suzuki HI, Miyazono K. Emerging complexity of microRNA generation cascades. J Biochem 2011; 149: 15-25.
11. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425: 415-419.
12. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003; 17: 3011-3016.
13. Klimczak D, Pączek L, Jażdżewski K, Kuch M. MicroRNAs: powerful regulators and potential diagnostic tools in cardiovascular disease. Kardiol Pol 2015; 73: 1-6.
14. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-840.
15. Ferrari R. RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract 2013; 2013: 269-278.
16. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol 2013; 167: 1677-1687.
17. Fournier D, Luft FC, Bader M, Ganten D, Andrade-Navarro MA. Emergence and evolution of the renin-angiotensin-aldosterone system. J Mol Med (Berl) 2012; 90: 495-508.
18. Jugdutt BI. Expanding Saga of the Renin-Angiotensin System: The Angiotensin II Counter-Regulatory AT2 Receptor Pathway. Circulation 2015; 131: 1380-1383.
19. Schweda F. Salt feedback on the renin-angiotensin-aldosterone system. Pflugers Arch 2015; 467: 565-576.
20. Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001: 104: E14-E18.
21. Head GA, Lukoshkova EV, Burke SL, Malpas SC, Lambert EA, Janssen BJ. Comparing spectral and invasive estimates of baroreflex gain. IEEE Eng Med Biol Mag 2001; 20: 43-52.
22. Jackson KL, Marques FZ, Watson AM, Palma-Rigo K, Nguyen-Huu TP, Morris BJ, et al. A novel interaction between sympathetic overactivity and aberrant regulation of renin by miR-181a in BPH/2J genetically hypertensive mice. Hypertension 2013; 62: 775-781.
23. Marques FZ, Campain AE, Tomaszewski M, Zukowska-Szczechowska E, Yang YH, Charchar FJ, et al. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension 2011; 58: 1093-1098.
24. Kohlstedt K, Trouvain C, Boettger T, Shi L, Fisslthaler B, Fleming I. AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145. Circ Res 2013; 112: 1150-1158.
25. Iio A, Takagi T, Miki K, Naoe T, Nakayama A, Akao Y. DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. Biochim Biophys Acta 2013; 1829: 1102-1110.
26. Hu B, Song JT, Qu HY, Bi CL, Huang XZ, Liu XX, et al. Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype. PLoS One 2014; 9: e96338.
27. Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, et al. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 2011; 406: 518-523.
28. Eskildsen TV, Jeppesen PL, Schneider M, Nossent AY, Sandberg MB, Hansen PB, et al. Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans. Int J Mol Sci 2013; 14: 11190-11207.
29. Chandra S, Narang R, Sreenivas V, Bhatia J, Saluja D, Srivastava K. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PLoS One 2014; 9: e101502.
30. Mottl AK, Shoham DA, North KE. Angiotensin II type 1 receptor polymorphisms and susceptibility to hypertension: a HuGE review. Genet Med 2008; 10: 560-574.
31. Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens 2011; 24: 241-246.
32. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281: 18277-18284.
33. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3’ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007; 81: 405-413.
34. Luo JQ, Wang LY, He FZ, Sun NL, Tang GF, Wen JG, et al. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics 2014; 15: 201-208.
35. Sober S, Laan M, Annilo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun 2010; 391: 727-732.
36. Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A 1998; 95: 9424-9429.
37. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9.
38. Patel SK, Velkoska E, Freeman M, Wai B, Lancefield TF, Burrell LM. From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol 2014; 5: 227.
39. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014; 16: 420.
40. Lambert DW, Lambert LA, Clarke NE, Hooper NM, Porter KE, Turner AJ, et al. Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. Clinical Science 2014; 127: 243-249.
41. Hewagama A, Gorelik G, Patel D, Liyanarachchi P, McCune WJ, Somers E, et al. Overexpression of X-linked genes in T cells from women with lupus. J Autoimmun 2013; 41: 60-71.
42. Chen LJ, Xu R, Yu HM, Chang Q, Zhong JC. The ACE2/Apelin Signaling, MicroRNAs, and Hypertension. Int J Hypertens 2015; 2015: 896861.
43. Gu Q, Wang B, Zhang XF, Ma YP, Liu JD, Wang XZ. Contribution of renin-angiotensin system to exercise-induced attenuation of aortic remodeling and improvement of endothelial function in spontaneously hypertensive rats. Cardiovasc Pathol 2014; 23: 298-305.
44. Kemp JR, Unal H, Desnoyer R, Yue H, Bhatnagar A, Karnik SS. Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin–angiotensin system. J Mol Cell Cardiol 2014; 75: 25-39.
45. Jenjaroenpun P, Kuznetsov VA. TTS mapping: integrative WEB tool for analysis of triplex formation target DNA sequences, G-quadruplets and non-protein coding regulatory DNA elements in the human genome. BMC Genomics 2009; 10: S9.
46. Padia SH, Carey RM. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers 2013; 465: 99-110.
47. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110: 483-495.
48. Obama T, Eguchi S. MicroRNA as a novel component of the tissue renin angiotensin system. J Mol Cell Cardiol 2014; 75: 98-99.